Harbinger Health announced a $100 million funding round led by Flagship Pioneering to advance its cancer detection technology13
The company introduced Resolve, a new category of blood-based multi-cancer detection tests designed to reduce diagnostic uncertainty between cancer suspicion and diagnosis13
Resolve is expected to be commercially available in the second half of 20263
The platform aims to minimize false negatives and false positives while enabling faster clinical decision-making1
The funding also supports further development of Harbinger's HarbingerHx software platform and the ongoing PROCARES prospective validation study, which is 88% enrolled13
Harbinger emerged from stealth in 2021 with $50 million from Flagship Pioneering and raised $140 million in Series B in 20231
The company's technology combines artificial intelligence with cancer biology insights to detect early-stage cancers through low-cost blood tests targeting multiple cancer types3
Sources:
1. https://www.fiercebiotech.com/medtech/harbinger-health-raises-100m-new-suite-blood-based-cancer-detection-tests
3. https://www.prnewswire.com/news-releases/harbinger-health-establishes-resolve-as-a-new-category-for-cancer-detection-302740706.html